Who
Karen Bernstein
Director
Company insider
Files Form 4 as: Director, Ovid Therapeutics; Director, Codiak BioSciences; Director, Achaogen; Director, Vitae Pharmaceuticals.
In numbers
- Trades disclosed
- 30
- Buys
- 2
- Sells
- 0
- Bought
- $83K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 30 Sep 2015
- Last trade
- 26 Feb 2026
- Last filed
- 2 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 26 Feb 2026filed 2 Mar 2026 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 20 Feb 2025filed 18 Jun 2025 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 12 Dec 2024filed 16 Dec 2024 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 22 Feb 2024filed 26 Feb 2024 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 23 Feb 2023filed 27 Feb 2023 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code M | —8,750 at $0.00 | filing |
| 16 Feb 2023filed 21 Feb 2023 | Codiak BioSciences | SEC FORM 4 Code M | —8,750 | filing |
| 17 Jun 2022filed 21 Jun 2022 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 17 Jun 2022filed 21 Jun 2022 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 8 Apr 2022filed 12 Apr 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,424 at $0.00 | filing |
| 16 Feb 2022filed 18 Feb 2022 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code A | —8,750 at $0.00 | filing |
| 3 Feb 2022filed 4 Feb 2022 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 18 Jun 2021filed 22 Jun 2021 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 11 Jun 2021filed 11 Jun 2021 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 17 May 2021filed 18 May 2021 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,750 at $0.00 | filing |
| 13 Oct 2020filed 15 Oct 2020 | Codiak BioSciencesoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 5 Jun 2020filed 8 Jun 2020 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,250 at $0.00 | filing |
| 13 Nov 2019filed 15 Nov 2019 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,437 at $0.00 | filing |
| 10 Jun 2019filed 1 Aug 2019 | OVID Ovid Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,813 at $0.00 | filing |
News
Ovid Therapeutics (NASDAQ:OVID) Stock Rated "Overweight" in New Coverage at Cantor FitzgeraldOVID · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Karen Bernstein; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.